Anixa Biosciences
ANIX
18 hedge funds and large institutions have $3.24M invested in Anixa Biosciences in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.63% less ownership
Funds ownership: 5.7% → 5.07% (-0.63%)
57% less capital inflows, than outflows
Capital inflows: $277K | Capital outflows: $648K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$106K |
| 2 |
Virtu Financial
New York
|
+$101K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$62.5K |
| 4 |
Bank of New York Mellon
New York
|
+$4.73K |
| 5 |
Morgan Stanley
New York
|
+$3.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$611K |
| 2 |
Two Sigma Securities
New York
|
-$28K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.86K |
| 5 |
Evercore Wealth Management
New York
|
-$1K |
ANIX Hedge Fund Activity: Q1 2018 in Review
18 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2018, worth a combined $3.24M — up 46% from $2.22M a quarter earlier.
Fund positioning in ANIX was balanced in Q1 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $106K. The largest seller was Vanguard Group, cutting an estimated $611K.
- 18 institutional investors held Anixa Biosciences (ANIX) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $3.24M of Anixa Biosciences stock for Q1 2018, up 46% quarter-over-quarter.
- 3 funds opened new Anixa Biosciences positions in Q1 2018 and 3 closed out, a net change of 0 holders.
- The largest Anixa Biosciences buyer in Q1 2018 was Goldman Sachs, an estimated $106K added.
- The largest Anixa Biosciences seller in Q1 2018 was Vanguard Group, an estimated $611K sold.
Based on aggregated 13F filings for Q1 2018.